Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine

Takeshi Inoue, Minoru Honda, Kunihiko Kawamura, Kiyoshi Tsuchiya, Takashi Suzuki, Koichi Ito, Ryoji Matsubara, Kaoru Shinohara, Tomohito Ishikane, Kuniko Sasaki, Shuken Boku, Daisuke Fujisawa, Yutaka Ono, Tsukasa Koyama

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study was undertaken to examine the long-term effectiveness and safety of switching to sertraline from other selective serotonin reuptake inhibitors (SSRIs) in the treatment of non-remitted or treatment-intolerant major depressive disorder. The study included 25 patients with major depressive disorder according to DSM-IV-TR criteria. None had achieved remission with paroxetine or fluvoxamine, but each had been used in an adequate dose for an adequate time period or had been intolerant of these SSRIs. Most patients (n= 22, 88%) were non-remitters. Switching was accomplished by gradual cross-titration and tapering. We conducted assessments at baseline and at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. Outcomes were assessed using the Quick Inventory of Depressive Symptomatology-Self-Report, Japanese version (QIDS-SRJ) score (primary outcome), the 17-item Hamilton Depression Rating Scale (HDRS), and the Clinical Global Impressions (CGI) scale. Mean QIDS-SRJ and HDRS scores improved significantly from baseline to week 8 and week 24. At the respective endpoints of weeks 8 and 24, remitters on QIDS-SRJ (≤ 5) were 2 of 25 (8%) and 4 of 25 (16%). At weeks 8 and 24, 11 of 25 (44%) were responders on QIDS-SRJ (≥ 50% reduction). Five patients (20%) terminated early, before week 8, because of side effects and/or lack of efficacy. These preliminary data suggest that the switching strategy from paroxetine or fluvoxamine to sertraline might be effective and well-tolerated in patients with non-remitted or treatment-intolerant major depressive disorder.

Original languageEnglish
Pages (from-to)223-227
Number of pages5
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume38
Issue number2
DOIs
Publication statusPublished - 2012 Aug 7
Externally publishedYes

Fingerprint

Fluvoxamine
Sertraline
Paroxetine
Major Depressive Disorder
Self Report
Equipment and Supplies
Serotonin Uptake Inhibitors
Depression
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Safety

Keywords

  • Fluvoxamine
  • Major depressive disorder
  • Non-remission
  • Paroxetine
  • Sertraline

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine. / Inoue, Takeshi; Honda, Minoru; Kawamura, Kunihiko; Tsuchiya, Kiyoshi; Suzuki, Takashi; Ito, Koichi; Matsubara, Ryoji; Shinohara, Kaoru; Ishikane, Tomohito; Sasaki, Kuniko; Boku, Shuken; Fujisawa, Daisuke; Ono, Yutaka; Koyama, Tsukasa.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 38, No. 2, 07.08.2012, p. 223-227.

Research output: Contribution to journalArticle

Inoue, T, Honda, M, Kawamura, K, Tsuchiya, K, Suzuki, T, Ito, K, Matsubara, R, Shinohara, K, Ishikane, T, Sasaki, K, Boku, S, Fujisawa, D, Ono, Y & Koyama, T 2012, 'Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 38, no. 2, pp. 223-227. https://doi.org/10.1016/j.pnpbp.2012.04.001
Inoue, Takeshi ; Honda, Minoru ; Kawamura, Kunihiko ; Tsuchiya, Kiyoshi ; Suzuki, Takashi ; Ito, Koichi ; Matsubara, Ryoji ; Shinohara, Kaoru ; Ishikane, Tomohito ; Sasaki, Kuniko ; Boku, Shuken ; Fujisawa, Daisuke ; Ono, Yutaka ; Koyama, Tsukasa. / Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012 ; Vol. 38, No. 2. pp. 223-227.
@article{c194f2aa9d2a464a8fd28279a43dbd89,
title = "Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine",
abstract = "This study was undertaken to examine the long-term effectiveness and safety of switching to sertraline from other selective serotonin reuptake inhibitors (SSRIs) in the treatment of non-remitted or treatment-intolerant major depressive disorder. The study included 25 patients with major depressive disorder according to DSM-IV-TR criteria. None had achieved remission with paroxetine or fluvoxamine, but each had been used in an adequate dose for an adequate time period or had been intolerant of these SSRIs. Most patients (n= 22, 88{\%}) were non-remitters. Switching was accomplished by gradual cross-titration and tapering. We conducted assessments at baseline and at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. Outcomes were assessed using the Quick Inventory of Depressive Symptomatology-Self-Report, Japanese version (QIDS-SRJ) score (primary outcome), the 17-item Hamilton Depression Rating Scale (HDRS), and the Clinical Global Impressions (CGI) scale. Mean QIDS-SRJ and HDRS scores improved significantly from baseline to week 8 and week 24. At the respective endpoints of weeks 8 and 24, remitters on QIDS-SRJ (≤ 5) were 2 of 25 (8{\%}) and 4 of 25 (16{\%}). At weeks 8 and 24, 11 of 25 (44{\%}) were responders on QIDS-SRJ (≥ 50{\%} reduction). Five patients (20{\%}) terminated early, before week 8, because of side effects and/or lack of efficacy. These preliminary data suggest that the switching strategy from paroxetine or fluvoxamine to sertraline might be effective and well-tolerated in patients with non-remitted or treatment-intolerant major depressive disorder.",
keywords = "Fluvoxamine, Major depressive disorder, Non-remission, Paroxetine, Sertraline",
author = "Takeshi Inoue and Minoru Honda and Kunihiko Kawamura and Kiyoshi Tsuchiya and Takashi Suzuki and Koichi Ito and Ryoji Matsubara and Kaoru Shinohara and Tomohito Ishikane and Kuniko Sasaki and Shuken Boku and Daisuke Fujisawa and Yutaka Ono and Tsukasa Koyama",
year = "2012",
month = "8",
day = "7",
doi = "10.1016/j.pnpbp.2012.04.001",
language = "English",
volume = "38",
pages = "223--227",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine

AU - Inoue, Takeshi

AU - Honda, Minoru

AU - Kawamura, Kunihiko

AU - Tsuchiya, Kiyoshi

AU - Suzuki, Takashi

AU - Ito, Koichi

AU - Matsubara, Ryoji

AU - Shinohara, Kaoru

AU - Ishikane, Tomohito

AU - Sasaki, Kuniko

AU - Boku, Shuken

AU - Fujisawa, Daisuke

AU - Ono, Yutaka

AU - Koyama, Tsukasa

PY - 2012/8/7

Y1 - 2012/8/7

N2 - This study was undertaken to examine the long-term effectiveness and safety of switching to sertraline from other selective serotonin reuptake inhibitors (SSRIs) in the treatment of non-remitted or treatment-intolerant major depressive disorder. The study included 25 patients with major depressive disorder according to DSM-IV-TR criteria. None had achieved remission with paroxetine or fluvoxamine, but each had been used in an adequate dose for an adequate time period or had been intolerant of these SSRIs. Most patients (n= 22, 88%) were non-remitters. Switching was accomplished by gradual cross-titration and tapering. We conducted assessments at baseline and at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. Outcomes were assessed using the Quick Inventory of Depressive Symptomatology-Self-Report, Japanese version (QIDS-SRJ) score (primary outcome), the 17-item Hamilton Depression Rating Scale (HDRS), and the Clinical Global Impressions (CGI) scale. Mean QIDS-SRJ and HDRS scores improved significantly from baseline to week 8 and week 24. At the respective endpoints of weeks 8 and 24, remitters on QIDS-SRJ (≤ 5) were 2 of 25 (8%) and 4 of 25 (16%). At weeks 8 and 24, 11 of 25 (44%) were responders on QIDS-SRJ (≥ 50% reduction). Five patients (20%) terminated early, before week 8, because of side effects and/or lack of efficacy. These preliminary data suggest that the switching strategy from paroxetine or fluvoxamine to sertraline might be effective and well-tolerated in patients with non-remitted or treatment-intolerant major depressive disorder.

AB - This study was undertaken to examine the long-term effectiveness and safety of switching to sertraline from other selective serotonin reuptake inhibitors (SSRIs) in the treatment of non-remitted or treatment-intolerant major depressive disorder. The study included 25 patients with major depressive disorder according to DSM-IV-TR criteria. None had achieved remission with paroxetine or fluvoxamine, but each had been used in an adequate dose for an adequate time period or had been intolerant of these SSRIs. Most patients (n= 22, 88%) were non-remitters. Switching was accomplished by gradual cross-titration and tapering. We conducted assessments at baseline and at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. Outcomes were assessed using the Quick Inventory of Depressive Symptomatology-Self-Report, Japanese version (QIDS-SRJ) score (primary outcome), the 17-item Hamilton Depression Rating Scale (HDRS), and the Clinical Global Impressions (CGI) scale. Mean QIDS-SRJ and HDRS scores improved significantly from baseline to week 8 and week 24. At the respective endpoints of weeks 8 and 24, remitters on QIDS-SRJ (≤ 5) were 2 of 25 (8%) and 4 of 25 (16%). At weeks 8 and 24, 11 of 25 (44%) were responders on QIDS-SRJ (≥ 50% reduction). Five patients (20%) terminated early, before week 8, because of side effects and/or lack of efficacy. These preliminary data suggest that the switching strategy from paroxetine or fluvoxamine to sertraline might be effective and well-tolerated in patients with non-remitted or treatment-intolerant major depressive disorder.

KW - Fluvoxamine

KW - Major depressive disorder

KW - Non-remission

KW - Paroxetine

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=84862850836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862850836&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2012.04.001

DO - 10.1016/j.pnpbp.2012.04.001

M3 - Article

VL - 38

SP - 223

EP - 227

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 2

ER -